Response to "Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy"
Am J Gastroenterol
.
2021 Dec 1;116(12):2474.
doi: 10.14309/ajg.0000000000001495.
Authors
Yung-Yin Cheng
1
2
,
Ming-Che Tsai
3
4
5
,
James Cheng-Chung Wei
5
6
7
Affiliations
1
Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung, Taiwan.
2
Department of Medical Imaging and Radiological Sciences, Chung Shan Medical University, Taichung, Taiwan.
3
Department of Emergency Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
4
College of Medicine, Chung Shan Medical University, Taichung, Taiwan.
5
Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan.
6
Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
7
Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
PMID:
34459468
DOI:
10.14309/ajg.0000000000001495
No abstract available
Publication types
Letter
Comment
MeSH terms
Angiotensin-Converting Enzyme 2
COVID-19*
Humans
Proton Pump Inhibitors* / adverse effects
Risk Factors
SARS-CoV-2
Substances
Proton Pump Inhibitors
Angiotensin-Converting Enzyme 2